After reaching an important support level, Abivax SA Sponsored ADR (ABVX) could be a good stock pick from a technical perspective. ABVX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

zacks.com - 2026-07-10 10:56:06

Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under intense scrutiny as an acquisition target by a larger peer.

cnbc.com - 2026-07-10 06:10:15

The sky is the limit for these companies.

fool.com - 2026-07-07 19:15:00

Shares of Abivax NASDAQ: ABVX were up more than 40% in the month ending July 6, after the company announced positive results from its late-stage (Phase 3) trial of its lead candidate, Obefazimod, which is being designed as a long-term maintenance treatment for ulcerative colitis (UC). The rally pushed ABVX nearly to its all-time high of $146.41, set in December 2025.

marketbeat.com - 2026-07-07 12:25:55

Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 7,360,000 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “Offering”), which includes the full exercise of the underwriters' option to purchase additional ADSs (the “Underwriters' Option”).

globenewswire.com - 2026-07-06 16:05:00

Shares rose 5% after the biotech moved to bolster its balance sheet through an upsized stock offering, signaling investor appetite in the wake of positive clinical-trial data.

wsj.com - 2026-07-02 05:25:00

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

globenewswire.com - 2026-07-02 02:00:00

Abivax SA raised $800 million in an ​expanded share sale on Wednesday after strong investor demand, valuing the French biotechnology company at nearly $11 ‌billion and easing pressure to pursue a near-term sale.

reuters.com - 2026-07-01 19:02:42

Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

globenewswire.com - 2026-07-01 09:06:00

Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m.

globenewswire.com - 2026-07-01 08:56:00

Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares

globenewswire.com - 2026-07-01 08:37:00

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m.

globenewswire.com - 2026-07-01 01:30:00

Abivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the launch of an underwritten public offering of approximately $600 million (approximately €527 million) of its American Depositary Shares (“ADSs”), each representing one ordinary share of Abivax, nominal value €0.01 per share (each, an “Ordinary Share”), in the United States (the “Offering”).

globenewswire.com - 2026-06-30 16:45:00

Abivax SA (NASDAQ:ABVX, EPA:ABVX, FRA:2X10, FRA:2X1) shares surged more than 40% on Tuesday after the French biotech released updated safety data from its late-stage ulcerative colitis program for its investigational drug obefazimod, easing earlier market concerns around reported cancer cases in the study. The company said the additional analysis showed that observed malignancy rates across its Phase 2 and Phase 3 program were consistent with background rates typically seen in patients with ulcerative colitis.

proactiveinvestors.com - 2026-06-30 13:16:54

Abivax SA (NASDAQ:ABVX, EPA:ABVX, FRA:2X10, FRA:2X1) shares surged more than 40% on Tuesday after the French biotech released updated safety data from its...

proactiveinvestors.com - 2026-06-30 09:15:00

The late-stage clinical trial data of the medicine, released late on Monday, showed that malignancies were in line with expected background rates. In this article ABVX

cnbc.com - 2026-06-30 03:14:25

ABIVAX Société Anonyme (ABVX) Discusses ABTECT Maintenance Part 2 Results and Updated Obefazimod Safety and Efficacy Data in Ulcerative Colitis Transcript

seekingalpha.com - 2026-06-30 03:02:12

Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, ​with the biotech calling the results a ‌boost to the safety profile of its late-stage program.

reuters.com - 2026-06-29 17:22:40

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3  Maintenance Safety Database

globenewswire.com - 2026-06-29 16:05:00

LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ: ABVX) for violations of the securities laws.

globenewswire.com - 2026-06-17 09:58:00

Los Angeles, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. ("Abivax" or "the Company") (NASDAQ: ABVX) for violations of the securities laws.

prnewswire.com - 2026-06-11 12:00:00

LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ: ABVX) for violations of the securities laws.

globenewswire.com - 2026-06-10 10:15:00

NEW YORK, June 9, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ABIVAX Societe Anonyme (NASDAQ: ABVX). Shareholders who purchased shares of ABVX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

prnewswire.com - 2026-06-09 09:00:00

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. ("Abivax" or "the Company") (NASDAQ: ABVX) for violations of the securities laws.

prnewswire.com - 2026-06-08 09:04:00

New York, New York--(Newsfile Corp. - June 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ABIVAX Societe Anonyme ("ABIVAX Societe Anonyme") (NASDAQ: ABVX) concerning potential violations of the federal securities laws. Abivax shareholders lost more than 40% of their investment value on June 2, 2026, as the stock plunged from a pre-announcement close of approximately $129.69 to as low as $71 per share midday after rare malignancy cases surfaced in the company's Phase 3 ABTECT ulcerative colitis trial for obefazimod.

newsfilecorp.com - 2026-06-04 15:24:00

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A

gurufocus.com - 2026-06-03 21:00:00

LOS ANGELES--(BUSINESS WIRE)---- $ABVX--ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm.

businesswire.com - 2026-06-03 20:53:00

The heavy selling pressure might have exhausted for Abivax SA Sponsored ADR (ABVX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

zacks.com - 2026-06-03 10:36:07

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX) PR Newswire N

gurufocus.com - 2026-06-02 22:00:00

Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of their value in a single session. NEW YORK, June 2, 2026 /PRNewswire/ -- Abivax (NASDAQ: ABVX) shareholders more than to 40% of their investment value on June 2, 2026, as the stock plunged from a pre-announcement close of approximately $129.69 to as low as $71 per share midday after rare malignancy cases surfaced in the company's Phase 3 ABTECT ulcerative colitis trial for obefazimod.

prnewswire.com - 2026-06-02 21:20:00

Abivax SA (ABVX) was hit hard after cancer cases in a pivotal trial created a fresh cloud over obefazimod, the French biotech's lead drug for moderately to seve

gurufocus.com - 2026-06-02 14:26:00

ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis Transcript

seekingalpha.com - 2026-06-02 09:51:51

Pre-Market Stock Futures: Futures are trading lower on Tuesday, but the technology tsunami continued on Monday, as all major indices dipped into the red early on news that Iran was halting the peace negotiations and would block the Strait of Hormuz. But that sell-off lasted until about noon, before a big reversal, which, by that... Here Are Tuesday's Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More

247wallst.com - 2026-06-02 08:11:52

The biotech said some patients developed cancer in a late-stage clinical trial for the bowel-disease drug that were unrelated to the treatment.

wsj.com - 2026-06-02 04:45:00

Abivax shares fell 31% even after the French biotech reported strong late-stage data for obefazimod, its experimental treatment for ulcerative colitis. The once-daily oral therapy met the main goal and all key secondary endpoints in a Phase 3 maintenance study, strengthening the case for a potential new option in a market still led by injectable biologics and other advanced treatments.

invezz.com - 2026-06-02 04:21:37

Abivax shares tumbled on Tuesday after the French biotech reported late-stage data for its experimental inflammatory bowel drug, with investors focusing on safety concerns even as the treatment ​showed strong efficacy.

reuters.com - 2026-06-02 04:21:03

Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update

cnbc.com - 2026-06-02 03:20:30

Abivax said on Monday its experimental drug for patients with ulcerative colitis, a type of chronic inflammatory disease, met the main goal ​of a closely watched late-stage trial.

reuters.com - 2026-06-01 18:38:56

Abivax stock crashed Monday after several patients developed cancer following a study of its ulcerative colitis treatment.

investors.com - 2026-06-01 18:29:31

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

globenewswire.com - 2026-06-01 16:05:00

Does Abivax SA Sponsored ADR (ABVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-05-28 13:01:13

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

globenewswire.com - 2026-05-22 16:05:00

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

globenewswire.com - 2026-05-05 02:00:00

Shares of Abivax SA Sponsored ADR (NASDAQ: ABVX - Get Free Report) have been given an average rating of "Moderate Buy" by the fifteen analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and one has issued a strong

defenseworld.net - 2026-04-24 02:12:49

Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models in Inflammatory Bowel Disease PARIS, France – April 22, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that nine scientific abstracts on obefazimod, its lead drug candidate for the treatment of moderately to severely active ulcerative colitis (UC), will be presented at the 2026 Digestive Disease Week (DDW) taking place May 2-5, 2026 in Chicago, IL. These presentations will highlight data from the Phase 3 ABTECT program, including efficacy, safety, and patient-reported outcomes, along with preclinical anti-fibrotic activity in two preclinical fibrosis models.

globenewswire.com - 2026-04-22 16:05:00

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

globenewswire.com - 2026-04-20 16:05:00